Clinical Trial Detail

NCT ID NCT01107665
Title Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, Irvine
Indications

skin melanoma

Therapies

Paclitaxel + Pazopanib

Age Groups: adult

No variant requirements are available.